# Hangzhou Eli Radiopharma Co., Ltd. funding rounds and investors

As of 13 Nov 2026, Hangzhou Eli Radiopharma Co., Ltd. has raised $60.0M across 1 verified round on record (amounts in other currencies converted to USD), plus 2 rounds still being checked; latest: nearly RMB 400 million Series A led by Bayland Capital and Huagai Capital, announced 11 Nov 2026.

Eli Radiopharma specializes in the innovation of radioactive diagnostic and therapeutic drugs for cancer and neurodegenerative diseases.

Website: https://eliradiopharma.com  
Headquarters: Hangzhou  
Page: https://fireround.dev/companies/eli-radiopharma

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-11 | Series A | nearly RMB 400 million | Bayland Capital, Huagai Capital | Bairui Capital, Bioclub Fund, Boyu Capital, CSPC & Growth Bio Fund, Delian Capital, Grand Flight Investment, Haibang Venture, Hongsheng Capital, Huaige Capital, InnoPinnacle Fund, KHK Fund, Longfeng Venture, Shenzhen Angel FOF Management, Skyfield Capital | [eliradiopharma.com](https://www.eliradiopharma.com/en/newsroom/press-release), [eliradiopharma.com](https://www.eliradiopharma.com/en/newsroom/press-release/29), [prnewswire.com](https://www.prnewswire.com/news-releases/eli-radiopharma-completes-series-a-financing-of-nearly-rmb-400-million-to-advance-innovative-radiopharmaceutical-pipeline-toward-clinical-development-302933121.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.